Cover Image

Glucagon-like peptide receptor agonists attenuate advanced glycation end products-induced inflammation in rat mesangial cells

Abstract Background Hyperglycemia-induced advanced glycation end products (AGEs) and receptor for AGEs (RAGE) production play major roles in progression of diabetic nephropathy. Anti-RAGE effect of peroxisome proliferator-activated receptor-delta (PPARδ) agonists was shown in previous studies. PPARδ...

Full description

Saved in:

Bibliographic Details
Main Authors:	Jui-Ting Chang (Author), Yao-Jen Liang (Author), Chia-Yu Hsu (Author), Chao-Yi Chen (Author), Po-Jung Chen (Author), Yi-Feng Yang (Author), Yen-Lin Chen (Author), Dee Pei (Author), Jin-Biou Chang (Author), Jyh-Gang Leu (Author)
Format:	Book
Published:	BMC, 2017-10-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

An Emerging Role of Glucagon-Like Peptide-1 in Preventing Advanced-Glycation-End-Product-Mediated Damages in Diabetes
by: Alessandra Puddu, et al.
Published: (2013)

Glycolaldehyde, an Advanced Glycation End Products Precursor, Induces Apoptosis via ROS-Mediated Mitochondrial Dysfunction in Renal Mesangial Cells
by: Min Ji Gu, et al.
Published: (2022)

Anti-inflammaging effects of vitamin D in human gingival fibroblasts with advanced glycation end product stimulation
by: Hung-Chieh Lu, et al.
Published: (2023)

Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
by: Seungah Lee, et al.
Published: (2017)

Cytoprotective Effect of Liposomal Puerarin on High Glucose-Induced Injury in Rat Mesangial Cells
by: Lassina Barro, et al.
Published: (2021)

Glucagon-Like Peptide-1 Triggers Protective Pathways in Pancreatic Beta-Cells Exposed to Glycated Serum
by: Alessandra Puddu, et al.
Published: (2013)

Expression of advanced glycation end products and receptors in gingival tissues of patients with noninsulin-dependent diabetes mellitus-associated periodontitis
by: Ya-Han Chang, et al.
Published: (2023)

Glucagon-like peptide-1 (GLP-1) agonists in the treatment of obesity
by: Magdalena Mazurek, et al.
Published: (2023)

The Impact of Glucagon-Like Peptide 1 Receptor Agonists on Bone Metabolism and Its Possible Mechanisms in Osteoporosis Treatment
by: Baocheng Xie, et al.
Published: (2021)

Indoxyl Sulfate, Not P-Cresyl Sulfate, is Associated with Advanced Glycation end Products in Patients on Long-Term Hemodialysis
by: Cheng-Jui Lin, et al.
Published: (2015)

Glucagon-like peptide-1 receptor agonists as add-on therapy to insulin for type 1 diabetes mellitus
by: Xinrui Tan, et al.
Published: (2023)

Pharmacoeconomic characteristics of agonists of receptors for glucagon-like peptide-1 and medicines on their base
by: I. N. Dyakov, et al.
Published: (2021)

Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease
by: Laurie L. Baggio, et al.
Published: (2021)

Glucagon-like peptide-1 receptor agonists and derivatives in the treatment of obesity - review
by: Michal Rabenda, et al.
Published: (2024)

Liraglutide Activates Glucagon-Like Peptide 1 Receptor to Attenuate Hyperglycemia through Endogenous Beta-Endorphin in Diabetic Rats
by: Kai-Chun Cheng, et al.
Published: (2020)

An Effective Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Improves Sarcopenic Obesity in Obese Mice by Modulating Skeletal Muscle Metabolism
by: Ren Q, et al.
Published: (2022)

Real-World Comparative Evaluation of Add-On Glucagon-like Peptide 1 Receptor Agonist in Type 2 Diabetes Treated with or without Insulin
by: Hsuan-Wen Chou, et al.
Published: (2022)

Potential Roles of Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs) in Nondiabetic Populations
by: Dan Xu, et al.
Published: (2022)

Risk of major adverse limb events in patients with type 2 diabetes mellitus receiving sodium glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists: A population-based retrospective cohort study
by: Yen-Chieh Lee, et al.
Published: (2022)

Iron and Advanced Glycation End Products: Emerging Role of Iron in Androgen Deficiency in Obesity
by: Seu-Hwa Chen, et al.
Published: (2020)

Effect of Glucagon-like peptide-1 receptor agonists on dyslipidemia in type 2 diabetes
by: Elizabeth A. Cristiano, et al.
Published: (2020)

Impact of Glucagon-like Peptide-1 Receptor Agonists on Intestinal Epithelial Cell Barrier
by: Takizawa Y., et al.
Published: (2024)

The Therapeutic Potential of Glucagon-like Peptide 1 Receptor Agonists in Traumatic Brain Injury
by: Anja Harej Hrkać, et al.
Published: (2024)

Amelioration of muscle wasting by glucagon‐like peptide‐1 receptor agonist in muscle atrophy
by: Yeonhee Hong, et al.
Published: (2019)

Decreased Risk of Anxiety in Diabetic Patients Receiving Glucagon-like Peptide-1 Receptor Agonist: A Nationwide, Population-Based Cohort Study
by: Wen-Hsuan Tsai, et al.
Published: (2022)

Health Technology Assessment: Evaluation of 7 Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus
by: Xie Z, et al.
Published: (2024)

Novel Small Molecule Glucagon-Like Peptide-1 Receptor Agonist S6 Stimulates Insulin Secretion From Rat Islets
by: Xiaohua Yang, et al.
Published: (2021)

Corrigendum: Decreased Risk of Anxiety in Diabetic Patients Receiving Glucagon-Like Peptide-1 Receptor Agonist: A Nationwide, Population-Based Cohort Study
by: Wen-Hsuan Tsai, et al.
Published: (2022)

Bolus Injection of Liraglutide Raises Plasma Glucose in Normal Rats by Activating Glucagon-like Peptide 1 Receptor in the Brain
by: Chia-Chen Hsu, et al.
Published: (2022)

Effects of glucagon-like peptide 1 receptor agonists on comorbidities in older patients with diabetes mellitus
by: Olusola F. Onoviran, et al.
Published: (2019)

Glucagon-like peptide-1 receptor agonists for treatment of diabetes and obesity: advantage of oral delivery
by: R. R. C. New, et al.
Published: (2024)

Glucagon-like peptide-1 receptor agonist exendin 4 ameliorates diabetes-associated vascular calcification by regulating mitophagy through the AMPK signaling pathway
by: Kui Chen, et al.
Published: (2024)

Angpt2 Induces Mesangial Cell Apoptosis through the MicroRNA-33-5p-SOCS5 Loop in Diabetic Nephropathy
by: Yi-Chun Tsai, et al.
Published: (2018)

Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic Fatty Liver Disease-Current Evidence
by: Emir M. Muzurović MD, MM, et al.
Published: (2022)

Economic analysis of glucagon like peptide-1 receptor agonists from the Saudi Arabia payer perspective
by: Nimer S. Alkhatib, et al.
Published: (2022)

Possible Mechanisms Underlying the Effects of Glucagon-Like Peptide-1 Receptor Agonist on Cocaine Use Disorder
by: Changliang Zhu, et al.
Published: (2022)

The Impact of Glucagon-like Peptide 1 Receptor Agonists on Obstructive Sleep Apnoea: A Scoping Review
by: Khang Duy Ricky Le, et al.
Published: (2024)

Healthcare professionals' perceptions and management of obesity & knowledge of glucagon, GLP‐1, GIP receptor agonists, and dual agonists
by: W. Timothy Garvey, et al.
Published: (2024)

Glucagon-like peptide-1 receptor agonists rescued diabetic vascular endothelial damage through suppression of aberrant STING signaling
by: Xuemin He, et al.
Published: (2024)

A Health Technology Assessment Based on Chinese Guidelines: Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Type 2 Diabetes Complicated with Cardiovascular Disease
by: Xie Z, et al.
Published: (2022)